Dedication<\/p>\n
List of Contributors<\/p>\n
Preface<\/p>\n
Chapter 1. Principles of Pharmacogenomics: Pharmacokinetic, Pharmacodynamic, and Clinical Implications<\/p>\n
Objectives<\/p>\n
Introduction<\/p>\n
Cytochrome P-450 Enzymes<\/p>\n
Non-CYP-450 Drug Metabolizing Enzymes<\/p>\n
Polymorphisms in Drug Transporter Genes<\/p>\n
Drug Target Genes<\/p>\n
Conclusion<\/p>\n
Questions for Discussion<\/p>\n
References<\/p>\n
Chapter 2. Translating Pharmacogenomic Research to Therapeutic Potentials<\/p>\n
Objectives<\/p>\n
Introduction<\/p>\n
Implementation of Biomarkers in Clinical Practice<\/p>\n
Incorporating Pharmacogenomics intoDrugDevelopment<\/p>\n
Conclusion<\/p>\n
Questions for Discussion<\/p>\n
References<\/p>\n
Chapter 3. Governmental and Academic Effortsto Advance the Field ofPharmacogenomics<\/p>\n
Objectives<\/p>\n
Introduction<\/p>\n
The Role of the National Institutes of Health<\/p>\n
The Role of the Food and Drug Administration and OtherInternational Government Agencies<\/p>\n
Activities of Non-U.S. Agencies<\/p>\n
Conclusion<\/p>\n
Questions for Discussion<\/p>\n
References<\/p>\n
Chapter 4. Pharmacogenomics in Cancer Therapeutics<\/p>\n
Objectives<\/p>\n
Introduction<\/p>\n
Role of Oncology Biomarkers<\/p>\n
Concepts in Targeted Cancer Therapy<\/p>\n
Oncology in the Postgenomic Era<\/p>\n
Challenges in Drug Development and Cancer Trials<\/p>\n
Seeking Pharmacogenomic Value<\/p>\n
Questions for Discussion<\/p>\n
References<\/p>\n
Chapter 4A. A Look to the Future: CancerEpigenetics<\/p>\n
Learning Objectives<\/p>\n
Introduction<\/p>\n
Histone Modification<\/p>\n
DNA Methylation<\/p>\n
Noncoding RNA (ncRNA)<\/p>\n
Conclusion<\/p>\n
Questions for Discussion<\/p>\n
References<\/p>\n
Chapter 5. Pharmacogenetics in Cardiovascular Diseases<\/p>\n
Objectives<\/p>\n
Introduction<\/p>\n
Pharmacogenomics of Antiplatelet Agents<\/p>\n
Warfarin Pharmacogenomics<\/p>\n
Other Genetic Contributions to Warfarin Dose Variability and Response<\/p>\n
Trials and Tribulations of Pharmacogenomics of Agents Used to Treat Dyslipidemia<\/p>\n
Pharmacogenomic Potential in Heart Failure<\/p>\n
Genetic Influences of Drug-Induced Arrhythmia<\/p>\n
Conclusion<\/p>\n
Discussion Points<\/p>\n
Discussion Questions<\/p>\n
References<\/p>\n
Chapter 5A. A Look to the Future: Cardiovascular Pharmacoepigenetics<\/p>\n
Learning objectives<\/p>\n
Introduction<\/p>\n
Opportunities<\/p>\n
Challenges<\/p>\n
Conclusion<\/p>\n
Questions for Discussion<\/p>\n
References<\/p>\n
Chapter 6. Pharmacogenomics in Psychiatric Disorders<\/p>\n
Objectives<\/p>\n
Introduction<\/p>\n
Polymorphisms in Proteins that Affect Drug Concentrations<\/p>\n
Polymorphisms in Proteins that Mediate Drug Response<\/p>\n
Application of Pharmacogenomics in Psychiatry<\/p>\n
Conclusion<\/p>\n
Questions for Discussion<\/p>\n
References<\/p>\n
Chapter 6A. A Look to the Future: Epigenetics in Psychiatric Disorders and Treatment<\/p>\n
Objectives<\/p>\n
Nature and Nurture Both Contribute to the Etiologies of Psychiatric Disorders<\/p>\n
Epigenetic Processes Are Likely to Contribute to the Biochemical Basis of Nurture<\/p>\n
Epigenetic Dysfunction Has Been Linked to Psychiatric and Neurological Disorders<\/p>\n
Epigenetic Processes May Be Critical to Treatment Response in Psychiatric Disorders<\/p>\n
Epigenetic Variation of Genes Regulating Pharmacokinetic Processes Is Likely to Influence Treatment Response<\/p>\n
Epigenetic Modifications of Drug Transporters<\/p>\n
Epigenetics and Adverse Drug Reactions<\/p>\n
Limitations of Epigenetic Biomarkers in Psychiatry<\/p>\n
Conclusion<\/p>\n
Questions for Discussion<\/p>\n
References<\/p>\n
Chapter 7. The Role of Pharmacogenomics in Diabetes, HIV Infection, and Pain Management<\/p>\n
Objectives<\/p>\n
Introduction<\/p>\n
Diabetes Overview<\/p>\n
Type 2 Diabetes Pharmacogenomics<\/p>\n
Challenges and Opportunities of Pharmacogenomics in Diabetes<\/p>\n
Pharmacogenomics and HIV<\/p>\n
Pharmacogenomics and Pain Control<\/p>\n
<\/p>\n
More here: Dedication List of Contributors Preface Chapter 1. Principles of Pharmacogenomics: Pharmacokinetic, Pharmacodynamic, and Clinical Implications Objectives Introduction Cytochrome P-450 Enzymes Non-CYP-450 Drug Metabolizing Enzymes Polymorphisms in Drug Transporter Genes Drug Target Genes Conclusion Questions for Discussion References Chapter 2. Translating Pharmacogenomic Research to Therapeutic Potentials Objectives Introduction Implementation of Biomarkers in Clinical Practice Incorporating Pharmacogenomics intoDrugDevelopment Conclusion Questions for Discussion References Chapter 3. Continue reading
\nPharmacogenomics - 1st Edition - Elsevier<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"